The Daily Dose: Another company bites the dust in Ebola vaccine development

The wheat appears to be separating from the chaff in the Ebola vaccine race. Glaxo-SmithKlein has ceded control to Johnson & Johnson. According to FierceBiotech, “GlaxoSmithKline has licensed Ebola vaccines to the Sabin Vaccine Institute. The agreement coincides with the news that Uganda has begun testing a Johnson & Johnson Ebola vaccine.” Survival of the fittest once again.

The South Korean biotech sector has taken a pounding lately. It hasn’t stopped yet. According to Evaluate, another high valuation company, Sillajen, has seen its only product in development get knee-capped. “The oncolytic virus Pexa-Vec, the company’s only meaningful asset, crashed as an interim futility analysis yielded a recommendation to halt its pivotal liver cancer trial.”

The digitization from the classical science laboratory to the so-called “smart lab” is well on its way. PharmaIQ did a survey of its readers and asked “What are the drivers to digitization?”

He’s been called the “Tropical Trump.” Brazilian President Jair Bolsonaro took office in January and since then he’s consistently undercut the nation’s scientists when it is politically expedient. According to Nature, “Brazil’s researchers have faced funding cuts and repeated attempts by the administration to roll back protections for the environment and Indigenous populations.” Is this another sign that the scientific community’s influence has started to wane?

IMAGE SOURCE: Creative Commons

The Scientific Inquirer needs your support. Please visit our Patreon page and discover ways that you can make a difference.

Leave a Reply

%d bloggers like this: